Chrysin-Anchored Silver and Gold Nanoparticle-Reduced Graphene Oxide Composites for Breast Cancer Therapy

The past decade has witnessed an extraordinary increase in research progress on ultrathin two-dimensional (2D) nanomaterials in the fields of condensed matter physics, materials science, and chemistry after the exfoliation of graphene from graphite in 2004. This unique class of nanomaterials has shown many unprecedented properties and thus is being explored for numerous promising applications. In this Perspective, I briefly review the state of the art in the development of ultrathin 2D nanomaterials and highlight their unique advantages. Then, I discuss the typical synthetic methods and some promising applications of ultrathin 2D nanomaterials together with some personal insights on the challenges in this research area. Finally, on the basis of the current achievement on ultrathin 2D nanomaterials, I give some personal perspectives on potential future research directions.

Successfully translating anti-cancer nanomedicines from pre-clinical proof of concept to demonstration of therapeutic value in the clinic is challenging. Having made significant advances with drug delivery technologies, we must learn from other areas of oncology drug development, where patient stratification and target-driven design have improved patient outcomes. We should evolve our nanomedicine development strategies to build the patient and disease into the line of sight from the outset. The success of small molecule targeted therapies has been significantly improved by employing a specific decision-making framework, such as AstraZeneca's 5R principle: right target/efficacy, right tissue/exposure, right safety, right patient, and right commercial potential. With appropriate investment and collaboration to generate a platform of evidence supporting the end clinical application, a similar framework can be established for enhancing nanomedicine translation and performance. Building informative data packages to answer these questions requires the following: (I) an improved understanding of the heterogeneity of clinical cancers and of the biological factors influencing the behaviour of nanomedicines in patient tumours; (II) a transition from formulation-driven research to disease-driven development; (III) the implementation of more relevant animal models and testing protocols; and (IV) the pre-selection of the patients most likely to respond to nanomedicine therapies. These challenges must be overcome to improve (the cost-effectiveness of) nanomedicine development and translation, and they are key to establishing superior therapies for patients.